Arbutus Biopharma (ABUS) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to -$93.7 million.
- Arbutus Biopharma's Enterprise Value rose 2667.73% to -$93.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$93.7 million, marking a year-over-year increase of 2667.73%. This contributed to the annual value of -$122.6 million for FY2024, which is 268.25% up from last year.
- Latest data reveals that Arbutus Biopharma reported Enterprise Value of -$93.7 million as of Q3 2025, which was up 2667.73% from -$98.1 million recorded in Q2 2025.
- In the past 5 years, Arbutus Biopharma's Enterprise Value registered a high of -$78.4 million during Q2 2021, and its lowest value of -$165.5 million during Q1 2022.
- For the 5-year period, Arbutus Biopharma's Enterprise Value averaged around -$130.0 million, with its median value being -$132.0 million (2021).
- As far as peak fluctuations go, Arbutus Biopharma's Enterprise Value plummeted by 39954.95% in 2021, and later skyrocketed by 3091.71% in 2025.
- Arbutus Biopharma's Enterprise Value (Quarter) stood at -$155.3 million in 2021, then rose by 5.41% to -$146.9 million in 2022, then increased by 14.23% to -$126.0 million in 2023, then grew by 2.68% to -$122.6 million in 2024, then grew by 23.59% to -$93.7 million in 2025.
- Its Enterprise Value was -$93.7 million in Q3 2025, compared to -$98.1 million in Q2 2025 and -$112.7 million in Q1 2025.